Compare APAM & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | IDYA |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | 145 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2011 | 2019 |
| Metric | APAM | IDYA |
|---|---|---|
| Price | $36.08 | $32.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 16 |
| Target Price | $47.00 | ★ $51.21 |
| AVG Volume (30 Days) | 610.5K | ★ 733.9K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.75% | N/A |
| EPS Growth | 10.66 | ★ 61.90 |
| EPS | ★ 4.05 | N/A |
| Revenue | ★ $1,196,688,000.00 | $218,710,000.00 |
| Revenue This Year | $7.55 | N/A |
| Revenue Next Year | $5.21 | $213.03 |
| P/E Ratio | $8.90 | ★ N/A |
| Revenue Growth | 7.63 | ★ 3024.43 |
| 52 Week Low | $32.75 | $13.45 |
| 52 Week High | $48.46 | $39.28 |
| Indicator | APAM | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 31.06 | 46.44 |
| Support Level | $35.02 | $29.15 |
| Resistance Level | $45.09 | $33.64 |
| Average True Range (ATR) | 0.98 | 1.35 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 18.43 | 31.85 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.